Tekmira Pharmaceuticals (TKMR)
Tekmira Pharmaceuticals Revenues: 3.763M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
TKMR Revenues Rankings
| Overall | 5th percentile | 4176 of 4431 |
| Sector | 21st percentile | 370 of 471 in Healthcare |
| Industry | 47th percentile | 9 of 17 in Diagnostic Substances |
TKMR Revenues Range, Past 5 Years
| Minimum | 1.90M | Mar 2008 |
| Maximum | 9.988M | Sep 2010 |
| Average | 3.853M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these TKMR related companies
TKMR News
From Earlier: Tekmira Provides Periodic Update to Shareholders Regarding Litigation
May 25, 7:05AM Benzinga
May 25, 7:05AM Benzinga
Tekmira Provides Corporate Update and Announces First Quarter 2012 Results
May 15, 4:00PM GlobeNewswire
May 15, 4:00PM GlobeNewswire
$TKMR forms bearish "Top Triangle" chart pattern. http://stks.co/3mUC
about 22 days ago by RecogniaEvents
about 22 days ago by RecogniaEvents
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter 2012 Results
May 09, 4:47PM GlobeNewswire
May 09, 4:47PM GlobeNewswire
Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data
Apr 20, 10:51AM GlobeNewswire
Apr 20, 10:51AM GlobeNewswire
Tekmira (TKMR) Narrows FY11 Loss on Lighter Sales; Sees Flat FY12 Revs
Mar 27, 4:12PM Street Insider
Mar 27, 4:12PM Street Insider
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2011 Audited Results
Mar 22, 4:40PM GlobeNewswire
Mar 22, 4:40PM GlobeNewswire
From Earlier: Tekmira Provides Update on Progress in USPTO Patent Interference Proceedings
Mar 15, 7:13AM Benzinga
Mar 15, 7:13AM Benzinga
Tekmira Provides Update on Progress in USPTO Patent Interference Proceedings
Mar 15, 12:50AM GlobeNewswire
Mar 15, 12:50AM GlobeNewswire
Breakout candidate: $ARWR http://stks.co/2l0W Other RNAi companies: $ALNY $TKMR
about 85 days ago by Xatta_Trading
about 85 days ago by Xatta_Trading
$TKMR forms bearish "Continuation Wedge" chart pattern. http://stks.co/2haW
about 87 days ago by RecogniaEvents
about 87 days ago by RecogniaEvents
Tekmira Expands Product Pipeline With RNAi Therapeutic for the Treatment of Alcohol Dependence
Mar 01, 8:00AM GlobeNewswire
Mar 01, 8:00AM GlobeNewswire
Tekmira Updates Financial Guidance: Cash Runway Further Extended Into Second Half of 2013
Feb 29, 11:57PM GlobeNewswire
Feb 29, 11:57PM GlobeNewswire
Tekmira Provides Periodic Update to Litigation; Alnylam Pharma Files Suit Against Tekmira
Jan 17, 4:33PM Benzinga
Jan 17, 4:33PM Benzinga
Tekmira Pharmaceuticals Receives Approval from FDA to Initiate TKM-Ebola Phase 1 Clinical Trial
Nov 28, 8:00AM GlobeNewswire
Nov 28, 8:00AM GlobeNewswire
Tekmira files for an injunction in the Supreme Court of British Columbia
Nov 16, 8:37AM FlyOnTheWall
Nov 16, 8:37AM FlyOnTheWall
Tekmira Provides Corporate Update and Announces Third Quarter 2011 Results
Nov 08, 4:00PM GlobeNewswire
Nov 08, 4:00PM GlobeNewswire
Tekmira Conference Call and Webcast Advisory: Third Quarter 2011 Operating Results and Corporate Update
Nov 03, 4:30PM GlobeNewswire
Nov 03, 4:30PM GlobeNewswire
Tekmira and Collaborators Demonstrate Efficacy of RNAi Against Hepatitis C Virus
Sep 12, 8:06AM Benzinga
Sep 12, 8:06AM Benzinga
Tekmira Pharmaceuticals (TKMR) Acquires Worldwide Exclusive License to Novel RNAi Platform
Aug 25, 8:21AM Street Insider
Aug 25, 8:21AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TKMR | 1.95 | -0.20 | -9.27% | 30.09M |
| TKF | 12.07 | -0.13 | -1.07% | |
| TKC | 11.09 | +0.26 | +2.40% | 9.530B |
| TK | 26.16 | -0.78 | -2.90% | 1.856B |
| TJX | 40.90 | -1.56 | -3.67% | 31.70B |
| TIVO | 8.07 | -0.47 | -5.50% | 1.044B |
| TD | 73.85 | -2.52 | -3.30% | 68.96B |
| TCX | 1.33 | -0.07 | -5.00% | 64.67M |
| TCRD | 12.33 | -0.35 | -2.76% | 256.39M |
| TCP | 40.78 | -0.22 | -0.54% | 2.192B |
